Reshape Lifesciences (OTCMKTS: ZYXI) and Zynex Inc. common stock (OTCMKTS:ZYXI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.
This table compares Reshape Lifesciences and Zynex Inc. common stock’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Zynex Inc. common stock||33.49%||205.15%||110.67%|
This is a summary of recent ratings for Reshape Lifesciences and Zynex Inc. common stock, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Zynex Inc. common stock||0||0||0||0||N/A|
Earnings and Valuation
This table compares Reshape Lifesciences and Zynex Inc. common stock’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Reshape Lifesciences||$1.29 million||0.35||-$33.81 million||($47.68)||0.00|
|Zynex Inc. common stock||$23.43 million||4.50||$7.36 million||$0.22||14.41|
Zynex Inc. common stock has higher revenue and earnings than Reshape Lifesciences. Reshape Lifesciences is trading at a lower price-to-earnings ratio than Zynex Inc. common stock, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
5.6% of Reshape Lifesciences shares are owned by institutional investors. Comparatively, 0.0% of Zynex Inc. common stock shares are owned by institutional investors. 0.1% of Reshape Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Reshape Lifesciences has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Zynex Inc. common stock has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Zynex Inc. common stock beats Reshape Lifesciences on 8 of the 11 factors compared between the two stocks.
About Reshape Lifesciences
ReShape Lifesciences Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; and ReShape Balloon system that uses balloon technology designed to take up room in the stomach to enable people lose weight. Its product portfolio also comprises ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.
About Zynex Inc. common stock
Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.